# Author's Accepted Manuscript

Effect of Fingolimod on Diffuse Brain Tissue Damage in Relapsing-Remitting Multiple Sclerosis Patients

Nicola De Stefano, Davorka Tomic, Ernst-Wilhelm Radue, Till Sprenger, Daniela Piani Meier, Dieter Häring, Maria Pia Sormani

www.elsevier.com/locate/msard

Cite this article as: Nicola De Stefano, Davorka Tomic, Ernst-Wilhelm Radue, Till Sprenger, Daniela Piani Meier, Dieter Häring and Maria Pia Sormani, Effec of Fingolimod on Diffuse Brain Tissue Damage in Relapsing-Remitting Multiple Sclerosis Patients, *Multiple Sclerosis and Related Disorders* http://dx.doi.org/10.1016/j.msard.2016.03.017

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version o the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Effect of Fingolimod on Diffuse Brain Tissue Damage in Relapsing-Remitting Multiple Sclerosis Patients

Nicola De Stefano[a]*, Davorka Tomic[b], Ernst-Wilhelm Radue[c], Till Sprenger[d], Daniela Piani Meier[b], Dieter Häring[b], Maria Pia Sormani[e]

[a]Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.

[b]Novartis Pharma AG, Basel, Switzerland.

[c]Medical Image Analysis Center (MIAC), University Hospital, Basel, Switzerland.

[d]Department of Neurology, DKD Helios Klinik Wiesbaden, Germany.

[e]University of Genoa, Genoa, Italy

douglas.arnold@mcgill.ca)

bnvsinger@earthlink.net)

destefano@unisi.it

*Correspondence to: Nicola De Stefano, MD PhD Dept. of Medicine, Surgery & Neuroscience, University of Siena, Viale Bracci 2, 53100 Siena, Italy.

Abstract

Background

Multiple sclerosis (MS) affects all areas of the brain resulting in both focal and diffuse damage. In Phase 3 clinical trials, fingolimod showed significant reductions in both focal lesions and rate of brain volume loss (BVL) in patients with relapsing-remitting MS.

Objective

To investigate if the effects of fingolimod 0.5 mg on BVL are mediated exclusively through its effects on focal damage or if fingolimod also acts independently in reducing diffuse damage.

Methods

This was a pooled post-hoc analysis of patients from two Phase 3 studies (FREEDOMS [N=1272] and FREEDOMS II [N=1083]), with no evidence of focal disease activity as defined by absence of gadolinium-enhancing lesions at baseline and new active lesions and clinical relapses at follow-up. The percent brain volume change (PBVC), as a measure of diffuse tissue damage, was assessed at Month (M) 12 and M24 by using the Structural Image Evaluation using Normalization of Atrophy (SIENA) method. A regression analysis was performed in the pooled intent-to-treat (ITT) population to quantify the treatment effect of fingolimod on BVL vs. placebo (PBO) in the overall population (unadjusted model), and whether this effect is sustained after adjusting for new active lesions and on-study relapses (adjusted model).

Results

Of 1088 patients, 638 (PBO, n=127; fingolimod, n=511) at M12 and 450 patients (PBO, n=68; fingolimod, n=382) at M24 showed no focal activity. Fingolimod significantly reduced PBVC by 65.5% over 12M (fingolimod vs. PBO: -0.16 vs. -0.45; p=0.001) and by 48.2% over 24M (-0.42 vs. -0.81; p=0.004). An absolute difference in PBVC of -0.27% (p<0.001) in favor of fingolimod vs. PBO over 24M was still evident in the pooled ITT population, after adjusting for active lesions and on-study relapses. The regression model suggests that 54% (-0.27%/-0.51%) of effects of fingolimod on PBVC are independent of its effects on visible focal damage.

2

Conclusions

The effect of fingolimod on diffuse damage is partly independent of its treatment effect on focal damage, suggesting that both inflammatory and neurodegenerative components of MS are affected.

Keywords: Relapsing-remitting Multiple Sclerosis; Focal damage; Diffuse damage; Brain Volume loss; Fingolimod

1. INTRODUCTION

Multiple sclerosis (MS) is traditionally seen as an inflammatory disease of the central nervous system (CNS) that is characterized by the presence of circumscribed demyelinated plaques in the cerebral white matter (WM).[1, 2] Recent post-mortem work has re-emphasized, however, that focal WM lesions are only part of the spectrum of MS pathology.[3] Alterations are also present in the so-called normal-appearing WM and in the grey matter,[4] confirming earlier pathologic observations that the disease process affects not only myelin, but also axons and neurons.[3-5] Magnetic resonance imaging (MRI) is widely used in the management of MS patients owing to its high sensitivity in detecting focal WM abnormalities. More recently, numerous studies have used MRI-based methods for a computed estimation of the brain volume loss (BVL) that accumulates throughout the course of the MS.[6] Indeed, these volumetric changes have shown great clinical relevance, due to their close correlation with patients' physical disability and cognitive impairment.[7, 8] MRI has been used to monitor the effects of disease-modifying therapies (DMTs) on brain volume.[9]

Fingolimod, a sphingosine-1-phosphate (S1P) receptor modulator, has been shown in three phase 3 studies to significantly reduce BVL, in addition to the significant

effects on MRI measures and on clinical endpoints in RRMS patients.[10-12] Moreover, a recent post-hoc analysis has suggested a complementary role of MRI lesions and BVL as potential surrogates for disability in the short term of clinical trials with fingolimod[13, 14] supporting the inclusion of BVL as one of the key outcome measures in the evaluation of therapeutic effects in RRMS.[10, 12]

In this context, it would be important to further evaluate the extent to which the effects of fingolimod on BVL are mediated through its well-described impact on focal damage (relapses and MRI lesions) alone, or by an additional effect on the diffuse damage in the non-lesional tissue. To explore this, we performed two different post-hoc analyses on the pooled data from the two phase 3, double-blind, randomized, FREEDOMS and FREEDOMS II trials: 1) we assessed the percent brain volume change (PBVC), as a marker of BVL, in a sub-group of patients with no evidence of focal disease activity, defined as absence of both clinical relapses and active lesions; 2) we quantified the treatment effect of fingolimod versus placebo that is mediated exclusively by PBVC measures in a statistical model using the pooled population of the two trials.

2.   METHODS

2.1.   *Patients and Study Design*

Data from both FREEDOMS (N=1272) and FREEDOMS II (N=1083) were pooled in the post-hoc analysis. FREEDOMS and FREEDOMS II (registered with ClinicalTrials.gov identifier NCT00289978 and NCT00355134), were placebo-controlled, double-blind, randomized, phase III studies in relapsing-remitting MS (RRMS). The study designs were similar and the inclusion/exclusion criteria of both trials have been previously described.[10, 12] Briefly, RRMS patients aged 18 to 55 years, with a score of 0 to 5.5 on the Expanded Disability Status Scale (EDSS) and

having one or more relapses in the previous year and/or two or more relapses in the previous two years were included. Eligible patients were randomized (1:1:1) to receive fingolimod 0.5 mg/day, 1.25 mg/day or placebo for two years. Data of the fingolimod 0.5 mg/day, 1.25 mg/day groups were pooled. The trials were both conducted in accordance with International Conference on Harmonization Guidelines for Good Clinical Practice and the ethical principles of the Declaration of Helsinki. The ethics committees and institutional review boards of all participating centers approved the study protocols. All participants provided written informed consent before any study-related procedures were performed.

2.2. *Statistical Analyses*

For the purpose of this study we performed two types of analyses on pooled data from the two trials:

Analysis 1: We assessed the PBVC, in a sub-group of patients with no evidence of focal disease activity, defined as absence of clinical relapses, gadolinium enhancing (Gd+) T1-weighted lesions at study entry and new active lesions (Gd+ T1 lesions and/or new/enlarging T2 lesions) during the follow-up period. In both trials, PBVC was measured by SIENA (Structural Image Evaluation using Normalization of Atrophy)[15] at Month 12 and Month 24. This subgroup analysis was conducted to determine if there is a difference in BVL between fingolimod-treated and placebo patients, who did not have evidence of focal disease activity. PBVC at Month 12 and at Month 24 in the subgroup with no activity was compared between treatment arms using an ANOVA model.

Analysis 2: A regression analysis was performed on the pooled population of the two trials with complete data on MRI lesions, relapses and PBVC over a 24-month

follow-up period, in order to confirm and quantify the treatment effect of fingolimod on BVL versus placebo, which are independent from its effect on focal disease activity.

Firstly, an unadjusted regression model was used with treatment as the only factor to define the overall treatment effect of fingolimod on PBVC over 2 years (vs. placebo). Secondly, an adjusted regression model with treatment, relapses (Yes/No) and active lesions (Yes/No) during the treatment period as factors was used to determine treatment effect on PBVC after adjusting for on-study relapse and lesion activity. In this way, the relative difference in the treatment effect between the unadjusted and the adjusted model represents the effect of fingolimod on PBVC, which is independent of its effect on MRI lesions and relapses.

3. RESULTS

Analysis 1: Of the pooled patients from FREEDOMS and FREEDOMS II, a subgroup of 638 patients (placebo, n=127; fingolimod, n=511) over a total of 1996 patients with a PBVC assessment at Month 12, and 450 patients (placebo, n=68; fingolimod, n=382) over a total of 1799 patients with a PBVC assessment at Month 24, showed no focal disease activity. The baseline characteristics are reported in Table 1. In patients with no focal activity, fingolimod-treated patients had a significant reduction in PBVC over 12 months (-0.16% BVL in fingolimod group vs. -0.45% in placebo group, difference = -0.29%, 95%CI = [-0.13% ; -0.46%], p=0.001) and on PBVC over 24 months (-0.42% in fingolimod group vs. -0.81% in placebo group, difference = -0.39%, 95%CI = [-0.12 ; -0.66%], p=0.004) vs. placebo patients (**Figure 1**).

Analysis 2: In the pooled population with complete data on MRI lesions, relapses and PBVC over the follow up period (placebo, n=577; fingolimod, n=1198), the

unadjusted regression model estimated the absolute difference in PBVC between

fingolimod versus placebo at Month 24 to be -0.51% (–0.79% vs. -1.30%; p<0.001;

Figure 2). A significant effect on PBVC in favor of fingolimod was still evident when

the model was adjusted for active lesions and on-study relapses, resulting in an

absolute difference of –0.27% (p<0.001). The regression model therefore suggests

that 54% (–0.27%/–0.51%) of the effects of fingolimod on PBVC, used here as a

measure of BVL, are not directly the result of reducing lesions and relapses.

4. DISCUSSION

BVL is a continuous process, occurring throughout the disease course of MS, at

rates higher than in non-MS subjects.[16] BVL correlates well with both current and

future disability and cognitive decline and, as such, has the potential to be used as

an outcome measure for evaluating DMTs in the treatment of MS.[13, 16] In Phase 3

studies of fingolimod, BVL correlated with MRI lesions, relapses and disability

progression. However, the MRI lesions and relapses that represent focal disease

activity and damage, accounted only for up to 50% of variability in brain volume

changes, with the rest remaining unexplained, potentially reflecting undetected,

diffuse damage.[10, 13]

In this post-hoc analysis, we assessed whether the treatment effect of fingolimod on

BVL could be related, at least in part, to its effect on diffuse tissue damage. The

main working hypothesis was, if MS patients without MRI and clinical signs of focal

damage in the placebo and the treated arms still show a difference in BVL, it is likely

that this effect is due to fingolimod's activity on pathological processes affecting non-

lesional tissue. Furthermore, we assessed the 'residual' treatment effect of

fingolimod on BVL, not explained by measurable focal disease activity, by comparing

unadjusted and adjusted models for relapses and new/enlarging T2 lesions. The

results of both analyses clearly showed that there is a significant portion of the treatment effect of fingolimod that is not explained by its effect on lesions/relapses and may be associated exclusively to diffuse BVL.

Several lines of evidence suggest that MS is not simply a focal demyelinating disease and that macroscopic lesions are just the tip of the iceberg of MS pathology. Indeed, the normal-appearing brain is profoundly abnormal, with a diffuse pathological process that appears to be distributed throughout the whole central nervous system.[3, 17] In such a context, the diffuse damage seems to occur, at least in part, independently from pathological changes within WM plaques.[1, 18] This strongly suggests that the brain of MS patients is affected by pathological changes in a more global sense.[3]

Numerous neuroimaging studies have used MRI-derived methods to assess BVL in MS as a measure of diffuse tissue damage.[6, 19] They have consistently shown that BVL can be observed from the earliest stages of MS and accumulates steadily over the course of the disease. Although in most studies significant BVL has been interpreted as largely due to the neurodegenerative processes occurring in MS,[20] it must be stressed that, in a complex disease such as MS, this may reflect different pathological substrates of both neuroinflammatory and neurodegenerative origins. They certainly include i) the shrinkage of WM lesions due to the loss of myelin, oligodendrocytes and axons and the contraction of astrocyte volume occurring during lesion maturation ii) the neuronal and glial loss in cortical grey matter (GM) lesions and iii) the Wallerian degeneration resulting from axonal transection in WM and GM lesions. The progressive volume loss occurring throughout the whole brain, however, is likely also the consequence of the diffuse inflammation, microglia activation and axonal injury occurring in the normal-appearing brain independently

from focal demyelination. Interestingly, in preclinical studies fingolimod has demonstrated the potential to act on at least some of these mechanisms, augmenting remyelination after toxin-induced demyelination, enhancing differentiation of oligodendrocyte progenitor cells and helping survival of mature oligodendrocytes, reducing astrogliosis and diminishing microglial activation.[18, 21, 22] In the present analysis, we made an attempt to disentangle the complex RRMS pathology. Results clearly showed that a significant portion of the treatment effect on BVL is present independently of its effect on clinical and MRI measures of active, focal damage. Whether this is due to a direct, neuroprotective effect of fingolimod via S1P receptor modulation on neural cells,[22-24] and/or due to its immune-mediated effects leading to the interruption of the destructive link between inflammation and neurodegeneration and pro-inflammatory S1P signaling cascade in the CNS partly involving astrocytes,[3, 25-27] cannot be established here.

5. CONCLUSION

By showing a significant treatment effect of fingolimod on BVL, which is independent of its effect on MRI lesions and relapses, the present study provides new evidence of the important paradigm shift that has taken place in our understanding of the disease process in MS: the disease is not only due to focal inflammatory WM lesions, but involves more subtle and diffuse damage throughout the whole brain. This leads to the immediate need of targeting MS treatment not only to focal inflammatory lesions but also to the neurodegeneration that occurs. In this context, MRI-based measurements of brain volume are paramount to assess and monitor the effects of DMTs that could meet this target.

The authors would like to thank patients from FREEDOMS and FREEDOMS II trials for their participation, as well as Sivaram Vedantam for writing assistance and Rishard Salie (Novartis, Medical communications) for editorial review assistance and in co-ordinating author reviews. All authors edited the manuscript for intellectual content, provided guidance during manuscript development and approved the final version submitted for publication.

Declaration of funding

Figure Legends:

Figure 1. Subgroup analysis[a]: Fingolimod treatment effect on percent brain volume change in patients with no baseline Gd+ lesions, no relapses and no new active lesions, at 12 and 24 months

[a]*Includes patients treated with both doses (0.5 mg and 1.25 mg)*

CI, confidence interval

Figure 2. Regression analysis[a]: Fingolimod treatment effect on diffuse damage is still apparent when adjusting[b] for focal damage

[a]*Includes patients treated with both doses (0.5 mg and 1.25 mg)*

[b]*Adjusted for new active lesions and on-study relapses*

CI, confidence interval

Table 1: Baseline characteristics

Characteristic	Patients with no focal activity at Month 12 (N=638)	Patients with no focal activity at Month 24 (N=450)
Age, years	41.2±8.5	41.5±8.5
Women,(%)	76	74
Time since first symptoms of MS	10.3±8.3	10.3±8.1
No history of disease-modifying treatment (%)	40	38
Relapses within previous 2 years, n	2.02±1.29	1.98±1.21
EDSS score (median, range)	2.0 (0-5.5)	2.0 (0-5.5)
T2 lesion volume, mm^3	3526±5356	3344±4954
T1 hypointense lesion volume, mm^3	1181±2479	1094±2113
Normalized brain volume, cm^3	1519±79	1519±79

Data are mean ± SD unless otherwise stated
EDSS, Expanded Disability Status Scale; MS, multiple sclerosis, SD, standard deviation.
*Patients pooled from FREEDOMS and FREEDOMS II.*

Figure 1:

Figure 2:

References

1. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. *Brain*. 2005; 128: 2705-12.

2. Love S. Demyelinating diseases. *Journal of clinical pathology*. 2006; 59: 1151-9.

3. Kutzelnigg A and Lassmann H. Pathology of multiple sclerosis and related inflammatory demyelinating diseases. *Handb Clin Neurol*. 2014; 122: 15-58.

4. Vrenken H and Geurts JJ. Gray and normal-appearing white matter in multiple sclerosis: an MRI perspective. *Expert review of neurotherapeutics*. 2007; 7: 271-9.

5. Lassmann H, Brück W and Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. *Brain Pathology*. 2007; 17: 210-8.

6. Filippi M, Rocca MA, Barkhof F, et al. Association between pathological and MRI findings in multiple sclerosis. *The Lancet Neurology*. 2012; 11: 349-60.

7. Roosendaal SD, Bendfeldt K, Vrenken H, et al. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. *Multiple Sclerosis Journal*. 2011; 17: 1098-106.

8. Sumowski JF, Rocca MA, Leavitt VM, et al. Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS. *Neurology*. 2014; 82: 1776-83.

9. De Stefano N, Airas L, Grigoriadis N, et al. Clinical relevance of brain volume measures in multiple sclerosis. *CNS drugs*. 2014; 28: 147-56.

10. Calabresi PA, Radue E-W, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. *The Lancet Neurology*. 2014; 13: 545-56.

11. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *The New England journal of medicine*. 2010; 362: 402-15.

12. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *The New England journal of medicine*. 2010; 362: 387-401.

13. Radue EW, Barkhof F, Kappos L, et al. Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. *Neurology*. 2015; 84: 784-93.

14. Sormani MP, De Stefano N, Francis G, et al. Fingolimod effect on brain volume loss independently contributes to its effect on disability. *Multiple sclerosis*. 2015; 21: 916-24.

15. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. *Neuroimage*. 2002; 17: 479-89.

16. Bermel RA and Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. *The Lancet Neurology*. 2006; 5: 158-70.

17. Seewann A, Vrenken H, van der Valk P, et al. Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis. *Archives of neurology*. 2009; 66: 601-9.

18. Airas L, Dickens AM, Elo P, et al. In Vivo PET Imaging Demonstrates Diminished Microglial Activation After Fingolimod Treatment in an Animal Model of Multiple Sclerosis. *Journal of Nuclear Medicine*. 2015; 56: 305-10.

19. Radue EW, Bendfeldt K, Mueller-Lenke N, Magon S and Sprenger T. Brain atrophy: an in-vivo measure of disease activity in multiple sclerosis. *Swiss medical weekly*. 2013; 143: w13887.

20. Barkhof F, Calabresi PA, Miller DH and Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. *Nature Reviews Neurology*. 2009; 5: 256-66.

21. Chun J and Brinkmann V. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). *Discovery medicine*. 2011; 12: 213-28.

22. Cui QL, Fang J, Kennedy TE, Almazan G and Antel JP. Role of p38MAPK in S1P receptor-mediated differentiation of human oligodendrocyte progenitors. *Glia*. 2014; 62: 1361-75.

23. Colombo E, Di Dario M, Capitolo E, et al. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide. *Annals of neurology*. 2014; 76: 325-37.

24. Groves A, Kihara Y and Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. *Journal of the neurological sciences*. 2013; 328: 9-18.

25. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. *Nature reviews Drug discovery*. 2010; 9: 883-97.

26. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. *Brain*. 2009; 132: 1175-89.

27. Centonze D, Muzio L, Rossi S, Furlan R, Bernardi G and Martino G. The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. *Cell Death & Differentiation*. 2010; 17: 1083-91.

Highlights

- Fingolimod treatment compared to placebo, resulted in a significant reduction of brain volume loss (BVL) over 12 months and 24 months.

- The effect of fingolimod on BVL is partially independent of its effect on focal damage (MRI lesions and relapses).

- This analysis provides additional evidence that, both inflammatory and neurodegenerative components are involved in multiple sclerosis disease processes.